These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 21711064)

  • 1. Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
    Dhillon S
    Drugs; 2011 Jun; 71(9):1209-31. PubMed ID: 21711064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.
    Dhillon S
    Drugs Aging; 2011 Nov; 28(11):927-30. PubMed ID: 22054233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
    Greenspoon J; Herrmann N; Adam DN
    CNS Drugs; 2011 Jul; 25(7):575-83. PubMed ID: 21623641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
    Frampton JE
    Drugs Aging; 2014 Aug; 31(8):639-49. PubMed ID: 24989628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivastigmine for Alzheimer's disease.
    Birks J; Grimley Evans J; Iakovidou V; Tsolaki M; Holt FE
    Cochrane Database Syst Rev; 2009 Apr; (2):CD001191. PubMed ID: 19370562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
    Cummings JL; Farlow MR; Meng X; Tekin S; Olin JT
    Clin Drug Investig; 2010; 30(1):41-9. PubMed ID: 19995097
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
    Wouters CJ; Dautzenberg L; Thissen A; Dautzenberg PL
    Tijdschr Gerontol Geriatr; 2010 Jun; 41(3):146-50. PubMed ID: 20593742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
    Darreh-Shori T; Jelic V
    Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
    Farlow MR; Alva G; Meng X; Olin JT
    Curr Med Res Opin; 2010 Feb; 26(2):263-9. PubMed ID: 19929593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivastigmine for Alzheimer's disease.
    Birks JS; Grimley Evans J
    Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease.
    Winblad B; Machado JC
    Expert Opin Drug Deliv; 2008 Dec; 5(12):1377-86. PubMed ID: 19040398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
    Schmidt R; Alf C; Bancher C; Benke T; Berek K; Dal-Bianco P; Führwürth G; Imarhiagbe D; Jagsch C; Lechner A; Rainer M; Reisecker F; Rotaru J; Uranüs M; Walter A; Winkler A; Wuschitz A
    Neuropsychiatr; 2009; 23(1):58-63. PubMed ID: 19272293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
    Reñé R; Ricart J; Hernández B;
    Neurologia; 2014 Mar; 29(2):86-93. PubMed ID: 23684446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.
    Amanatkar HR; Grossberg GT
    Expert Rev Neurother; 2014 Oct; 14(10):1119-25. PubMed ID: 25201245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
    Sadowsky CH; Farlow MR; Meng X; Olin JT
    Int J Clin Pract; 2010 Jan; 64(2):188-93. PubMed ID: 20089009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
    Pregelj P
    Psychogeriatrics; 2012 Sep; 12(3):165-71. PubMed ID: 22994614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.
    Yang LP; Keating GM
    CNS Drugs; 2007; 21(11):957-65. PubMed ID: 17927299
    [No Abstract]   [Full Text] [Related]  

  • 18. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
    Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
    Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
    Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
    Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
    Cagnin A; Cester A; Costa B; Ermani M; Gabelli C; Gambina G;
    Neurol Sci; 2015 Mar; 36(3):457-63. PubMed ID: 25394739
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.